Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults


Cite item

Full Text

Abstract

:Mantle Cell Lymphoma (MCL) is an aggressive subtype of Non-hodgkin's Lymphoma (NHL). Bruton Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase, and is one of the therapeutic targets for B-cell-driven malignancies. Approved covalent BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib are associated with treatment limitations due to off-target side effects and the development of C481 substitution resistance mutations. Pirtobrutinib was approved by the US FDA on January 27, 2023, for the treatment of relapsed or refractory mantle cell lymphoma, including the resistance to covalent BTK inhibitors. In this perspective, physicochemical properties, synthesis, dosage and administration, mechanism of action, pharmacodynamics, pharmacokinetics, drug interactions, and treatment-emergent adverse events of pirtobrutinib are discussed.

About the authors

Surya De

Department of Chemistry, Conju-Probe

Author for correspondence.
Email: info@benthamscience.net

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J. Clin., 2021, 71(3), 209-249. doi: 10.3322/caac.21660 PMID: 33538338
  2. Armitage, J.O.; Longo, D.L. Mantle-cell lymphoma. N. Engl. J. Med., 2022, 386(26), 2495-2506. doi: 10.1056/NEJMra2202672 PMID: 35767440
  3. Al-Mansour, M. Treatment landscape of relapsed/refractory mantle cell lymphoma: An updated review. Clin. Lymphoma Myeloma Leuk., 2022, 22(11), e1019-e1031. doi: 10.1016/j.clml.2022.07.017 PMID: 36068158
  4. Jensen, J.L.; Mato, A.R.; Pena, C.; Roeker, L.E.; Coombs, C.C. The potential of pirtobrutinib in multiple B-cell malignancies. Ther. Adv. Hematol., 2022, 13. doi: 10.1177/20406207221101697 PMID: 35747462
  5. Wen, T.; Wang, J.; Shi, Y.; Qian, H.; Liu, P. Inhibitors targeting Bruton’s tyrosine kinase in cancers: Drug development advances. Leukemia, 2021, 35(2), 312-332. doi: 10.1038/s41375-020-01072-6 PMID: 33122850
  6. Mato, A.R.; Shah, N.N.; Jurczak, W.; Cheah, C.Y.; Pagel, J.M.; Woyach, J.A.; Fakhri, B.; Eyre, T.A.; Lamanna, N.; Patel, M.R.; Alencar, A.; Lech-Maranda, E.; Wierda, W.G.; Coombs, C.C.; Gerson, J.N.; Ghia, P.; Le Gouill, S.; Lewis, D.J.; Sundaram, S.; Cohen, J.B.; Flinn, I.W.; Tam, C.S.; Barve, M.A.; Kuss, B.; Taylor, J.; Abdel-Wahab, O.; Schuster, S.J.; Palomba, M.L.; Lewis, K.L.; Roeker, L.E.; Davids, M.S.; Tan, X.N.; Fenske, T.S.; Wallin, J.; Tsai, D.E.; Ku, N.C.; Zhu, E.; Chen, J.; Yin, M.; Nair, B.; Ebata, K.; Marella, N.; Brown, J.R.; Wang, M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet, 2021, 397(10277), 892-901. doi: 10.1016/S0140-6736(21)00224-5 PMID: 33676628
  7. Cohen, J.B.; Shah, N.N.; Alencar, A.J.; Gerson, J.N.; Patel, M.R.; Fakhri, B.; Jurczak, W.; Tan, X.N.; Lewis, K.L.; Fenske, T.; Coombs, C.C.; Flinn, I.W.; Lewis, D.J.; Gouill, S.L.; Palomba, M.L.; Woyach, J.A.; Pagel, J.M.; Lamanna, N.; Barve, M.A.; Ghia, P.; Eyre, T.A.; Zinzani, P.L.; Ujjani, C.S.; Koh, Y.; Izutsu, K.; Lech-Maranda, E.; Tam, C.S.; Sundaram, S.; Yin, M.; Nair, B.; Tsai, D.E.; Balbas, M.; Mato, A.R.; Cheah, C.Y.; Wang, M.L. MCL-133 pirtobrutinib, a highly selective, non-covalent (Reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study. Clin. Lymphoma Myeloma Leuk., 2022, 22(Suppl. 2), S394-S395. doi: 10.1016/S2152-2650(22)01569-5 PMID: 36164120
  8. Ito, R.; Eyre, T.A.; Shah, N.N.; Gouill, S.L.; Dreyling, M.; Vandenberghe, E.; Jurczak, W.; Wang, Y.; Cheah, C.Y.; Gandhi, M.; Chay, C.; Sharman, J.; Andorsky, D.J.; Song, Y.; Stark, A.; Muthig, V.; Wang, M.L. MCL-135 BRUIN MCL-321, a Phase 3 open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma (Trial in Progress). Clin. Lymphoma Myeloma Leuk., 2022, 22(Suppl. 2), S395-S396. doi: 10.1016/S2152-2650(22)01570-1 PMID: 36164121
  9. Eyre, T.A.; Shah, N.N.; Dreyling, M.; Jurczak, W.; Wang, Y.; Cheah, C.Y.; Song, Y.; Gandhi, M.; Chay, C.; Sharman, J.; Andorsky, D.J.; Messersmith, H.M.; Ruppert, A.S.; Muthig, V.A.; Ito, R.; Wang, M.L. BRUIN MCL-321: Phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma. Future Oncol., 2022, 18(36), 3961-3969. doi: 10.2217/fon-2022-0976 PMID: 36377973
  10. Gomez, E.B.; Ebata, K.; Randeria, H.S.; Rosendahl, M.S.; Cedervall, E.P.; Morales, T.H.; Hanson, L.M.; Brown, N.E.; Gong, X.; Stephens, J.R.; Wu, W.; Lippincott, I.; Ku, K.S.; Walgren, R.A.; Abada, P.B.; Ballard, J.A.; Allerston, C.K.; Brandhuber, B.J. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood, 2023, 142(1), 62-72. doi: 10.1182/blood.2022018674
  11. Aslan, B.; Kismali, G.; Iles, L.R.; Manyam, G.C.; Ayres, M.L.; Chen, L.S.; Gagea, M.; Bertilaccio, M.T.S.; Wierda, W.G.; Gandhi, V. Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J., 2022, 12(5), 80. doi: 10.1038/s41408-022-00675-9 PMID: 35595730
  12. Wang, E.; Mi, X.; Thompson, M.C.; Montoya, S.; Notti, R.Q.; Afaghani, J.; Durham, B.H.; Penson, A.; Witkowski, M.T.; Lu, S.X.; Bourcier, J.; Hogg, S.J.; Erickson, C.; Cui, D.; Cho, H.; Singer, M.; Totiger, T.M.; Chaudhry, S.; Geyer, M.; Alencar, A.; Linley, A.J.; Palomba, M.L.; Coombs, C.C.; Park, J.H.; Zelenetz, A.; Roeker, L.; Rosendahl, M.; Tsai, D.E.; Ebata, K.; Brandhuber, B.; Hyman, D.M.; Aifantis, I.; Mato, A.; Taylor, J.; Abdel-Wahab, O. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N. Engl. J. Med., 2022, 386(8), 735-743. doi: 10.1056/NEJMoa2114110 PMID: 35196427
  13. Nakhoda, S.; Vistarop, A.; Wang, Y.L. Resistance to bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-hodgkin lymphoma. Br. J. Haematol., 2023, 200(2), 137-149. doi: 10.1111/bjh.18418 PMID: 36029036
  14. Michot, J.M.; Ribrag, V. Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors. Lancet, 2021, 397(10277), 855-857. doi: 10.1016/S0140-6736(21)00235-X PMID: 33676615
  15. Delgado, A.J.A.; Eary, C.T.; Fennell, J.W.; Frank, S.A.; Magnus, N.A.; Mcfaddin, E.A.; Rothhaar, R.R.; Spencer, S.R.; Vaid, R.K. Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl) -1h-pyrazole-4-carboxamide. US Patent WO2022056100A1, 2020.
  16. Alu, A.; Lei, H.; Han, X.; Wei, Y.; Wei, X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies. J. Hematol. Oncol., 2022, 15(1), 138. doi: 10.1186/s13045-022-01353-w PMID: 36183125
  17. Zain, R.; Vihinen, M. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front. Immunol., 2021, 12, 694853. doi: 10.3389/fimmu.2021.694853 PMID: 34349760
  18. Liu, Y.; Yan, F.; Jiang, V.C.; Li, Y.; Che, Y.; McIntosh, J.; Jordan, A.; Hou, I.; Nie, L.; Jin, J.; Wang, W.; Lee, H.H.; Yao, Y.; Wang, M. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma. Haematologica, 2022, 108(5), 1412-1416. doi: 10.3324/haematol.2022.282031 PMID: 36475521
  19. De, S.K. Cancers of the blood. In: Fundamentals of Cancer Detection, Treatment, and Prevention; Wiley, 2022; pp. 67-105.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers